On Monday, GSK plc GSK stock is trading higher on highly positive clinical data from two separate lung cancer trials, ...

GSK PLC GSK +1.87% shares rose 4.74% to £18.55 Monday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX -0.28% rising 0.44% to 10,697.57.

GSK plc (NYSE:GSK) is advancing its experimental seasonal influenza vaccine into late-stage development after encouraging mid ...

According to Sharecast on September 18, 2026, Berenberg upgraded GSK from Hold to Buy and lifted its target price on the stock from GBP 20 to GBP 22, arguing that recent business-development ...

Key Points Interested in GSK PLC Sponsored ADR? Here are five stocks we like better. GSK is expanding oncology across lung, ...

GSK plc stock (NYSE: GSK) trades at $38 per share, about 20% below its peak level of over $47 seen in April 2022. In contrast, its peer Bristol Myers Squibb stock (NYSE: BMY) saw a 48% decline over ...

GSK plc GSK has entered into an agreement to acquire an investigational trispecific T-cell engager (TCE) from Chimagen ...

GSK plc (NYSE:GSK) plans to close its vaccine manufacturing facility in Dresden, Germany, by summer 2027, putting 641 jobs at ...

GSK plc is reinventing itself as a pure-play biopharma company, betting on vaccines and specialty medicines to outpace rivals like Pfizer and Sanofi while reshaping investor expectations. GSK plc is ...

GSK PLC licensor Hansoh Pharmaceutical Group Co. Ltd., announced positive overall survival (OS) data from ARTEMIS-008, its pivotal phase III trial in China evaluating the B7-H3-targeted antibody-drug ...

GSK plc presented positive registrational data to potentially expand Jideytro (zidesamtinib) to first-line ROS1-positive non-small cell lung cancer. 94% objective response rate at 15.2 months ...

Previously, GSK had agreed with Chimagen to acquire CMG1A46, a clinical-stage dual CD19 and CD20-targeted TCE currently in phase I trials for B-cell malignancies and B-cell dependent autoimmune ...